BR112018002130A2 - anticorpo de domínio único e proteínas derivadas respectivas contra um ligante de morte programada (pdl1) - Google Patents
anticorpo de domínio único e proteínas derivadas respectivas contra um ligante de morte programada (pdl1)Info
- Publication number
- BR112018002130A2 BR112018002130A2 BR112018002130-0A BR112018002130A BR112018002130A2 BR 112018002130 A2 BR112018002130 A2 BR 112018002130A2 BR 112018002130 A BR112018002130 A BR 112018002130A BR 112018002130 A2 BR112018002130 A2 BR 112018002130A2
- Authority
- BR
- Brazil
- Prior art keywords
- pdl1
- programmed death
- death ligand
- single domain
- domain antibody
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/74—Inducing cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Abstract
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510465481.8A CN106397592A (zh) | 2015-07-31 | 2015-07-31 | 针对程序性死亡配体(pd-l1)的单域抗体及其衍生蛋白 |
CN201510465481.8 | 2015-07-31 | ||
PCT/CN2016/092680 WO2017020802A1 (zh) | 2015-07-31 | 2016-08-01 | 针对程序性死亡配体(pd-l1)的单域抗体及其衍生蛋白 |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112018002130A2 true BR112018002130A2 (pt) | 2018-09-11 |
Family
ID=57942455
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112018002130-0A BR112018002130A2 (pt) | 2015-07-31 | 2016-08-01 | anticorpo de domínio único e proteínas derivadas respectivas contra um ligante de morte programada (pdl1) |
Country Status (15)
Country | Link |
---|---|
US (2) | US20180291103A1 (pt) |
EP (2) | EP3330290A4 (pt) |
JP (2) | JP6946289B2 (pt) |
KR (1) | KR102138447B1 (pt) |
CN (4) | CN106397592A (pt) |
AU (1) | AU2016302951B2 (pt) |
BR (1) | BR112018002130A2 (pt) |
CA (1) | CA2994339C (pt) |
HK (2) | HK1251591A1 (pt) |
MX (1) | MX2018001387A (pt) |
MY (1) | MY195474A (pt) |
NZ (1) | NZ739499A (pt) |
PH (1) | PH12018500233A1 (pt) |
RU (1) | RU2715595C2 (pt) |
WO (2) | WO2017020802A1 (pt) |
Families Citing this family (117)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
CA2978942A1 (en) | 2015-03-13 | 2016-09-22 | Cytomx Therapeutics, Inc. | Anti-pdl1 antibodies, activatable anti-pdl1 antibodies, and methods of use thereof |
CN106397592A (zh) * | 2015-07-31 | 2017-02-15 | 苏州康宁杰瑞生物科技有限公司 | 针对程序性死亡配体(pd-l1)的单域抗体及其衍生蛋白 |
EP3371208A1 (en) | 2015-11-02 | 2018-09-12 | Five Prime Therapeutics, Inc. | Cd80 extracellular domain polypeptides and their use in cancer treatment |
CN107216389B (zh) * | 2016-03-18 | 2022-03-29 | 和迈生物科技有限公司 | 抗pd-l1纳米抗体及其编码序列和用途 |
US9567399B1 (en) | 2016-06-20 | 2017-02-14 | Kymab Limited | Antibodies and immunocytokines |
JP7461741B2 (ja) | 2016-06-20 | 2024-04-04 | カイマブ・リミテッド | 抗pd-l1およびil-2サイトカイン |
WO2018029474A2 (en) | 2016-08-09 | 2018-02-15 | Kymab Limited | Anti-icos antibodies |
ES2899036T3 (es) | 2016-08-04 | 2022-03-09 | Innovent Biologics Suzhou Co Ltd | Nanocuerpo anti-PD-L1 y su uso |
CN109689688B (zh) | 2016-08-09 | 2023-06-13 | 科马布有限公司 | 抗icos抗体 |
WO2018083248A1 (en) | 2016-11-03 | 2018-05-11 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses & methods |
EP3565841A1 (en) * | 2017-01-06 | 2019-11-13 | Crescendo Biologics Limited | Single domain antibodies to programmed cell death (pd-1) |
US11377497B2 (en) | 2017-01-23 | 2022-07-05 | Suzhou Alphamab Co., Ltd. | PD-L1 binding polypeptide or composite |
CN108456251A (zh) * | 2017-02-21 | 2018-08-28 | 上海君实生物医药科技股份有限公司 | 抗pd-l1抗体及其应用 |
EP3596118A4 (en) | 2017-03-15 | 2021-04-07 | Cue Biopharma, Inc. | PROCESSES FOR MODULATING AN IMMUNE RESPONSE |
US11789010B2 (en) | 2017-04-28 | 2023-10-17 | Five Prime Therapeutics, Inc. | Methods of treatment with CD80 extracellular domain polypeptides |
US11624326B2 (en) | 2017-05-21 | 2023-04-11 | Bj Energy Solutions, Llc | Methods and systems for supplying fuel to gas turbine engines |
CN107164410B (zh) * | 2017-05-27 | 2019-09-03 | 上海优卡迪生物医药科技有限公司 | 一种基于octs技术的前列腺癌car-t治疗载体及其构建方法和应用 |
WO2018222949A1 (en) | 2017-06-01 | 2018-12-06 | Cytomx Therapeutics, Inc. | Activatable anti-pdl1 antibodies, and methods of use thereof |
GB201709808D0 (en) | 2017-06-20 | 2017-08-02 | Kymab Ltd | Antibodies |
CN109096396B (zh) * | 2017-06-20 | 2022-01-04 | 华兰生物工程股份有限公司 | 一种抗pd-l1人源化纳米抗体及其应用 |
CN111051350B (zh) * | 2017-09-07 | 2022-11-01 | 苏州丁孚靶点生物技术有限公司 | 包含信号调节蛋白α的免疫缀合物 |
CN109485726B (zh) * | 2017-09-13 | 2022-07-08 | 和迈生物科技有限公司 | 放射性标记抗纳米抗体在癌症的预后、诊断中的应用 |
WO2019096121A1 (en) * | 2017-11-17 | 2019-05-23 | Nanjing Legend Biotech Co., Ltd. | Single-domain antibodies and variants thereof against pd-l1 |
WO2019122882A1 (en) | 2017-12-19 | 2019-06-27 | Kymab Limited | Bispecific antibody for icos and pd-l1 |
GB201721338D0 (en) | 2017-12-19 | 2018-01-31 | Kymab Ltd | Anti-icos Antibodies |
EP3733716A4 (en) * | 2017-12-26 | 2021-11-24 | Nanjing GenScript Biotech Co., Ltd. | DIMERAL FUSION PROTEIN USING ANTIBODY FC REGION AS A SKELETON AND ASSOCIATED USE |
WO2019149219A1 (zh) * | 2018-02-05 | 2019-08-08 | 思路迪(北京)医药科技有限公司 | 抗-cd3免疫毒素联合抗-pd-l1单域抗体治疗癌症的应用 |
CN110144010B9 (zh) * | 2018-02-14 | 2021-01-05 | 上海洛启生物医药技术有限公司 | 阻断型pd-l1驼源单域抗体及其用途 |
GB201802573D0 (en) | 2018-02-16 | 2018-04-04 | Crescendo Biologics Ltd | Therapeutic molecules that bind to LAG3 |
CA3092421A1 (en) * | 2018-03-01 | 2019-09-06 | Vrije Universiteit Brussel | Human pd-l1-binding immunoglobulins |
CN110343181B (zh) * | 2018-04-08 | 2022-04-08 | 苏州康宁杰瑞生物科技有限公司 | 针对凝血因子ix(fix)的单域抗体 |
EP3802613A4 (en) * | 2018-06-05 | 2022-03-09 | Jiangsu Alphamab Biopharmaceuticals Co., Ltd. | DIMERE AND ITS USE |
JP7332194B2 (ja) * | 2018-06-29 | 2023-08-23 | スーチョウ スマートヌクライド バイオファーマシューティカル カンパニー リミテッド | Pd-l1結合ポリペプチドおよびそれらの使用 |
US20220127364A1 (en) * | 2019-02-01 | 2022-04-28 | Innovent Biologics (Suzhou) Co., Ltd. | Novel anti-pd-l1 antibody and uses thereof |
CN109929037B (zh) | 2019-04-01 | 2023-03-17 | 华博生物医药技术(上海)有限公司 | 针对程序性死亡配体的结合物及其应用 |
CN110003333B (zh) * | 2019-04-12 | 2022-11-18 | 深圳普瑞金生物药业股份有限公司 | 多肽、pd-l1单域抗体、核苷酸序列及试剂盒 |
US11560845B2 (en) | 2019-05-15 | 2023-01-24 | Bj Energy Solutions, Llc | Mobile gas turbine inlet air conditioning system and associated methods |
EP3976090A1 (en) | 2019-05-24 | 2022-04-06 | Pfizer Inc. | Combination therapies using cdk inhibitors |
CN116987191A (zh) * | 2019-06-27 | 2023-11-03 | 启愈生物技术(上海)有限公司 | 抗PD-L1纳米抗体及其Fc融合蛋白和应用 |
CN114072175A (zh) | 2019-07-04 | 2022-02-18 | 江苏康宁杰瑞生物制药有限公司 | 治疗肿瘤的物质和方法 |
WO2021024020A1 (en) | 2019-08-06 | 2021-02-11 | Astellas Pharma Inc. | Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer |
CN112409483A (zh) * | 2019-08-22 | 2021-02-26 | 浙江道尔生物科技有限公司 | 抗pd-l1纳米抗体 |
CN112442122B (zh) * | 2019-09-04 | 2021-09-21 | 上海洛启生物医药技术有限公司 | 阻断型pd-1纳米抗体及其编码序列和用途 |
CN114222759B (zh) * | 2019-09-06 | 2023-06-06 | 北京拓界生物医药科技有限公司 | 抗pd-1单域抗体、其衍生蛋白及其医药用途 |
CN112480253B (zh) * | 2019-09-12 | 2022-09-20 | 普米斯生物技术(珠海)有限公司 | 一种抗pd-l1纳米抗体及其衍生物和用途 |
CA3092829C (en) | 2019-09-13 | 2023-08-15 | Bj Energy Solutions, Llc | Methods and systems for supplying fuel to gas turbine engines |
US11015536B2 (en) | 2019-09-13 | 2021-05-25 | Bj Energy Solutions, Llc | Methods and systems for supplying fuel to gas turbine engines |
US11604113B2 (en) | 2019-09-13 | 2023-03-14 | Bj Energy Solutions, Llc | Fuel, communications, and power connection systems and related methods |
US11002189B2 (en) | 2019-09-13 | 2021-05-11 | Bj Energy Solutions, Llc | Mobile gas turbine inlet air conditioning system and associated methods |
CA3092865C (en) | 2019-09-13 | 2023-07-04 | Bj Energy Solutions, Llc | Power sources and transmission networks for auxiliary equipment onboard hydraulic fracturing units and associated methods |
US10989180B2 (en) | 2019-09-13 | 2021-04-27 | Bj Energy Solutions, Llc | Power sources and transmission networks for auxiliary equipment onboard hydraulic fracturing units and associated methods |
CA3197583A1 (en) | 2019-09-13 | 2021-03-13 | Bj Energy Solutions, Llc | Fuel, communications, and power connection systems and related methods |
US10815764B1 (en) | 2019-09-13 | 2020-10-27 | Bj Energy Solutions, Llc | Methods and systems for operating a fleet of pumps |
US10895202B1 (en) | 2019-09-13 | 2021-01-19 | Bj Energy Solutions, Llc | Direct drive unit removal system and associated methods |
US11015594B2 (en) | 2019-09-13 | 2021-05-25 | Bj Energy Solutions, Llc | Systems and method for use of single mass flywheel alongside torsional vibration damper assembly for single acting reciprocating pump |
CN114430746B (zh) * | 2019-09-25 | 2023-09-01 | 上海药明生物技术有限公司 | 新型抗pd-l1抗体 |
EP4047021A4 (en) * | 2019-10-17 | 2023-11-22 | Jiangsu Alphamab Biopharmaceuticals Co., Ltd. | BISPECIFIC OX40/PD1-L1 ANTIBODIES |
WO2021083335A1 (zh) * | 2019-10-30 | 2021-05-06 | 三优生物医药(上海)有限公司 | Pd-l1结合分子 |
US20230015590A1 (en) * | 2019-12-04 | 2023-01-19 | Jiangsu Alphamab Biopharmaceuticals Co., Ltd. | Bispecific fusion protein for tumor treatment |
JP2023504531A (ja) * | 2019-12-04 | 2023-02-03 | 江蘇康寧杰瑞生物制薬有限公司 | 腫瘍治療のための二重特異性融合タンパク質と抗Her2抗体の組合せ |
CN110964101A (zh) * | 2019-12-13 | 2020-04-07 | 山东民康生物科技有限公司 | 一种纳米抗体制备方法 |
EP4083210A1 (en) | 2019-12-27 | 2022-11-02 | Interoligo Corporation | Anti-cancer immunotherapeutic composition for treating cancer |
CN111393527B (zh) * | 2019-12-27 | 2022-03-08 | 源道隆(苏州)医学科技有限公司 | 可结合pd-l1的多肽及其应用 |
BR112022014487A2 (pt) * | 2020-01-21 | 2022-09-27 | Wuxi Biologics Shanghai Co Ltd | Anticorpo bispecífico anti-pd-l1/vegf e usos do mesmo |
JP2023519412A (ja) * | 2020-03-31 | 2023-05-10 | ビオテウス・インコーポレイテッド | 抗pd-l1およびpd-l2抗体ならびにその誘導体および用途 |
EP4144758A4 (en) * | 2020-04-22 | 2024-05-15 | Mabwell Shanghai Bioscience Co Ltd | SINGLE VARIABLE DOMAIN ANTIBODIES TARGETING AND DERIVED FROM HUMAN PROGRAMMED DEATH LIGAND 1 (PD-L1) |
US11708829B2 (en) | 2020-05-12 | 2023-07-25 | Bj Energy Solutions, Llc | Cover for fluid systems and related methods |
US10968837B1 (en) | 2020-05-14 | 2021-04-06 | Bj Energy Solutions, Llc | Systems and methods utilizing turbine compressor discharge for hydrostatic manifold purge |
US11428165B2 (en) | 2020-05-15 | 2022-08-30 | Bj Energy Solutions, Llc | Onboard heater of auxiliary systems using exhaust gases and associated methods |
US11208880B2 (en) | 2020-05-28 | 2021-12-28 | Bj Energy Solutions, Llc | Bi-fuel reciprocating engine to power direct drive turbine fracturing pumps onboard auxiliary systems and related methods |
US10961908B1 (en) | 2020-06-05 | 2021-03-30 | Bj Energy Solutions, Llc | Systems and methods to enhance intake air flow to a gas turbine engine of a hydraulic fracturing unit |
US11109508B1 (en) | 2020-06-05 | 2021-08-31 | Bj Energy Solutions, Llc | Enclosure assembly for enhanced cooling of direct drive unit and related methods |
US11208953B1 (en) | 2020-06-05 | 2021-12-28 | Bj Energy Solutions, Llc | Systems and methods to enhance intake air flow to a gas turbine engine of a hydraulic fracturing unit |
US11022526B1 (en) | 2020-06-09 | 2021-06-01 | Bj Energy Solutions, Llc | Systems and methods for monitoring a condition of a fracturing component section of a hydraulic fracturing unit |
US10954770B1 (en) | 2020-06-09 | 2021-03-23 | Bj Energy Solutions, Llc | Systems and methods for exchanging fracturing components of a hydraulic fracturing unit |
US11066915B1 (en) | 2020-06-09 | 2021-07-20 | Bj Energy Solutions, Llc | Methods for detection and mitigation of well screen out |
US11125066B1 (en) | 2020-06-22 | 2021-09-21 | Bj Energy Solutions, Llc | Systems and methods to operate a dual-shaft gas turbine engine for hydraulic fracturing |
US11939853B2 (en) | 2020-06-22 | 2024-03-26 | Bj Energy Solutions, Llc | Systems and methods providing a configurable staged rate increase function to operate hydraulic fracturing units |
US11933153B2 (en) | 2020-06-22 | 2024-03-19 | Bj Energy Solutions, Llc | Systems and methods to operate hydraulic fracturing units using automatic flow rate and/or pressure control |
US11028677B1 (en) | 2020-06-22 | 2021-06-08 | Bj Energy Solutions, Llc | Stage profiles for operations of hydraulic systems and associated methods |
US11473413B2 (en) | 2020-06-23 | 2022-10-18 | Bj Energy Solutions, Llc | Systems and methods to autonomously operate hydraulic fracturing units |
US11466680B2 (en) | 2020-06-23 | 2022-10-11 | Bj Energy Solutions, Llc | Systems and methods of utilization of a hydraulic fracturing unit profile to operate hydraulic fracturing units |
US11149533B1 (en) | 2020-06-24 | 2021-10-19 | Bj Energy Solutions, Llc | Systems to monitor, detect, and/or intervene relative to cavitation and pulsation events during a hydraulic fracturing operation |
US11220895B1 (en) | 2020-06-24 | 2022-01-11 | Bj Energy Solutions, Llc | Automated diagnostics of electronic instrumentation in a system for fracturing a well and associated methods |
KR20230035576A (ko) | 2020-07-07 | 2023-03-14 | 비온테크 에스이 | Hpv 양성 암 치료용 rna |
US11193360B1 (en) | 2020-07-17 | 2021-12-07 | Bj Energy Solutions, Llc | Methods, systems, and devices to enhance fracturing fluid delivery to subsurface formations during high-pressure fracturing operations |
CA3190722A1 (en) * | 2020-08-05 | 2022-02-10 | Ohio State Innovation Foundation | Adapter polypeptides and methods of using the same |
EP3992208A1 (en) * | 2020-11-03 | 2022-05-04 | Randox Laboratories Ltd | Anti-pd-l1 vhh antibodies |
WO2022122026A1 (en) * | 2020-12-11 | 2022-06-16 | Genesail (Shanghai) Co., Ltd. | A modified oncolytic virus, composition and use thereof |
TW202245808A (zh) | 2020-12-21 | 2022-12-01 | 德商拜恩迪克公司 | 用於治療癌症之治療性rna |
WO2022135667A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Therapeutic rna for treating cancer |
WO2022135666A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Treatment schedule for cytokine proteins |
CN112724208A (zh) * | 2020-12-25 | 2021-04-30 | 中山大学 | 一种SADS-CoV重组S蛋白胞外段及其制备方法与应用 |
CN114763384B (zh) * | 2021-01-14 | 2023-03-17 | 立凌生物制药(苏州)有限公司 | 靶向pd-1的单域抗体及其衍生物和用途 |
US11685784B2 (en) * | 2021-03-24 | 2023-06-27 | China Medical University Hospital | Anti-immune-checkpoint nanobody and nucleic acid encoding sequence thereof, and uses of the same |
US11795227B2 (en) | 2021-03-24 | 2023-10-24 | Shine-On Biomedical Co., Ltd. | Immunomodulation and anti-tumor-related nanobody and nucleic acid encoding sequence thereof, and uses of the same |
TW202304506A (zh) | 2021-03-25 | 2023-02-01 | 日商安斯泰來製藥公司 | 涉及抗claudin 18.2抗體的組合治療以治療癌症 |
WO2022237897A1 (zh) * | 2021-05-14 | 2022-11-17 | 迈威(上海)生物科技股份有限公司 | 一种抗pd-l1单域抗体及其衍生蛋白 |
US20220396623A1 (en) | 2021-05-18 | 2022-12-15 | Kymab Limited | Uses of anti-icos antibodies |
US11639654B2 (en) | 2021-05-24 | 2023-05-02 | Bj Energy Solutions, Llc | Hydraulic fracturing pumps to enhance flow of fracturing fluid into wellheads and related methods |
AU2022281461A1 (en) | 2021-05-25 | 2024-01-04 | Edelweiss Immune Inc | C-x-c motif chemokine receptor 6 (cxcr6) binding molecules, and methods of using the same |
GB202107994D0 (en) | 2021-06-04 | 2021-07-21 | Kymab Ltd | Treatment of cancer |
WO2022261017A1 (en) * | 2021-06-09 | 2022-12-15 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Cross species single domain antibodies targeting pd-l1 for treating solid tumors |
KR20240046323A (ko) | 2021-07-13 | 2024-04-08 | 비온테크 에스이 | 암에 대한 병용 요법에 있어서 cd40 및 cd137에 대한 다중특이 결합제 |
WO2023040999A1 (zh) | 2021-09-18 | 2023-03-23 | 江苏康宁杰瑞生物制药有限公司 | 包含pd-l1抗原结合片段的组合物及其用途 |
WO2023051926A1 (en) | 2021-09-30 | 2023-04-06 | BioNTech SE | Treatment involving non-immunogenic rna for antigen vaccination and pd-1 axis binding antagonists |
WO2023057882A1 (en) | 2021-10-05 | 2023-04-13 | Pfizer Inc. | Combinations of azalactam compounds with a pd-1 axis binding antagonist for the treatment of cancer |
TW202333802A (zh) | 2021-10-11 | 2023-09-01 | 德商拜恩迪克公司 | 用於肺癌之治療性rna(二) |
CN116063518A (zh) * | 2021-10-29 | 2023-05-05 | 广东菲鹏制药股份有限公司 | 一种pd-l1结合分子及其应用 |
WO2023079428A1 (en) | 2021-11-03 | 2023-05-11 | Pfizer Inc. | Combination therapies using tlr7/8 agonist |
WO2023083439A1 (en) | 2021-11-09 | 2023-05-19 | BioNTech SE | Tlr7 agonist and combinations for cancer treatment |
WO2023213764A1 (en) * | 2022-05-02 | 2023-11-09 | Transgene | Fusion polypeptide comprising an anti-pd-l1 sdab and a member of the tnfsf |
WO2023213763A1 (en) * | 2022-05-02 | 2023-11-09 | Transgene | Poxvirus encoding a binding agent comprising an anti- pd-l1 sdab |
WO2023222854A1 (en) | 2022-05-18 | 2023-11-23 | Kymab Limited | Uses of anti-icos antibodies |
CN117736323A (zh) * | 2022-09-21 | 2024-03-22 | 三优生物医药(上海)有限公司 | 抗pd-l1抗体及其用途 |
CN115925947B (zh) * | 2022-09-27 | 2023-08-22 | 上海百英生物科技股份有限公司 | 一种亲和力成熟方法及抗人pd-l1单域抗体的亲和力成熟 |
Family Cites Families (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104356236B (zh) * | 2005-07-01 | 2020-07-03 | E.R.施贵宝&圣斯有限责任公司 | 抗程序性死亡配体1(pd-l1)的人单克隆抗体 |
CN101104640A (zh) * | 2006-07-10 | 2008-01-16 | 苏州大学 | 抗人pd-l1单克隆抗体制备及应用 |
WO2008071447A2 (en) | 2006-12-15 | 2008-06-19 | Ablynx N.V. | Amino acid sequences that modulate the interaction between cells of the immune system |
EP3222634A1 (en) * | 2007-06-18 | 2017-09-27 | Merck Sharp & Dohme B.V. | Antibodies to human programmed death receptor pd-1 |
CA2698419C (en) * | 2007-09-07 | 2019-11-12 | Edward Dolk | Binding molecules with multiple binding sites, compositions comprising the same and uses thereof |
EP2315778A2 (en) * | 2008-07-18 | 2011-05-04 | Domantis Limited | Compositions monovalent for cd28 binding and methods of use |
AU2009296392B2 (en) * | 2008-09-26 | 2016-06-02 | Dana-Farber Cancer Institute, Inc. | Human anti-PD-1, PD-L1, and PD-L2 antibodies and uses therefor |
EP2356150A2 (en) | 2008-10-10 | 2011-08-17 | Emergent Product Development Seattle, LLC | Tcr complex immunotherapeutics |
PE20120341A1 (es) * | 2008-12-09 | 2012-04-24 | Genentech Inc | Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t |
KR101573109B1 (ko) | 2009-11-24 | 2015-12-01 | 메디뮨 리미티드 | B7―h1에 대한 표적화된 결합 물질 |
LT2785375T (lt) * | 2011-11-28 | 2020-11-10 | Merck Patent Gmbh | Anti-pd-l1 antikūnai ir jų panaudojimas |
US9856320B2 (en) * | 2012-05-15 | 2018-01-02 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting PD-1/PD-L1 signaling |
CN115093480A (zh) * | 2012-05-31 | 2022-09-23 | 索伦托药业有限公司 | 与pd-l1结合的抗原结合蛋白 |
CN104560884A (zh) * | 2013-10-25 | 2015-04-29 | 苏州思坦维生物技术有限责任公司 | 拮抗抑制程序性死亡受体pd-1与其配体结合的单克隆抗体及分泌它的杂交瘤细胞系与用途 |
CN104558177B (zh) * | 2013-10-25 | 2020-02-18 | 苏州思坦维生物技术股份有限公司 | 拮抗抑制程序性死亡受体pd-1与其配体结合的单克隆抗体及其编码序列与用途 |
WO2015103602A1 (en) * | 2014-01-06 | 2015-07-09 | The Trustees Of The University Of Pennsylvania | Pd1 and pdl1 antibodies and vaccine combinations and use of same for immunotherapy |
CN103772501A (zh) * | 2014-01-27 | 2014-05-07 | 成都生物制品研究所有限责任公司 | Vegf抗体及其制备方法和用途 |
US10618963B2 (en) * | 2014-03-12 | 2020-04-14 | Yeda Research And Development Co. Ltd | Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS |
US10519237B2 (en) * | 2014-03-12 | 2019-12-31 | Yeda Research And Development Co. Ltd | Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS |
AU2015292590B2 (en) * | 2014-07-24 | 2020-01-16 | 2Seventy Bio, Inc. | BCMA chimeric antigen receptors |
CN106397592A (zh) * | 2015-07-31 | 2017-02-15 | 苏州康宁杰瑞生物科技有限公司 | 针对程序性死亡配体(pd-l1)的单域抗体及其衍生蛋白 |
CN107216389B (zh) | 2016-03-18 | 2022-03-29 | 和迈生物科技有限公司 | 抗pd-l1纳米抗体及其编码序列和用途 |
WO2018005552A1 (en) * | 2016-06-27 | 2018-01-04 | Achillion Pharmaceuticals, Inc. | Quinazoline and indole compounds to treat medical disorders |
KR20240023677A (ko) * | 2016-12-05 | 2024-02-22 | 쥐원 쎄라퓨틱스, 인크. | 화학요법 레지멘 동안의 면역 반응의 보존 |
US11377497B2 (en) * | 2017-01-23 | 2022-07-05 | Suzhou Alphamab Co., Ltd. | PD-L1 binding polypeptide or composite |
TWI674261B (zh) * | 2017-02-17 | 2019-10-11 | 美商英能腫瘤免疫股份有限公司 | Nlrp3 調節劑 |
EP3596118A4 (en) * | 2017-03-15 | 2021-04-07 | Cue Biopharma, Inc. | PROCESSES FOR MODULATING AN IMMUNE RESPONSE |
WO2018222949A1 (en) * | 2017-06-01 | 2018-12-06 | Cytomx Therapeutics, Inc. | Activatable anti-pdl1 antibodies, and methods of use thereof |
WO2018223002A1 (en) * | 2017-06-01 | 2018-12-06 | Xencor, Inc. | Bispecific antibodies that bind cd 123 cd3 |
WO2018223004A1 (en) * | 2017-06-01 | 2018-12-06 | Xencor, Inc. | Bispecific antibodies that bind cd20 and cd3 |
CN111051350B (zh) * | 2017-09-07 | 2022-11-01 | 苏州丁孚靶点生物技术有限公司 | 包含信号调节蛋白α的免疫缀合物 |
AU2019228128A1 (en) * | 2018-03-02 | 2020-09-03 | Cdr-Life Ag | Trispecific antigen binding proteins |
MX2021004709A (es) * | 2018-10-31 | 2021-06-04 | Genentech Inc | Metodo y medicamento para tratar cancer insensible a inhibidor de se?alizacion de pd-1/pd-l1. |
-
2015
- 2015-07-31 CN CN201510465481.8A patent/CN106397592A/zh active Pending
-
2016
- 2016-08-01 NZ NZ73949916A patent/NZ739499A/en unknown
- 2016-08-01 CN CN201911218460.0A patent/CN111116747B/zh active Active
- 2016-08-01 CN CN201680031015.1A patent/CN107636013B/zh active Active
- 2016-08-01 WO PCT/CN2016/092680 patent/WO2017020802A1/zh active Application Filing
- 2016-08-01 RU RU2018107427A patent/RU2715595C2/ru active
- 2016-08-01 MY MYPI2018700386A patent/MY195474A/en unknown
- 2016-08-01 MX MX2018001387A patent/MX2018001387A/es unknown
- 2016-08-01 CN CN201680031072.XA patent/CN107849130B/zh active Active
- 2016-08-01 KR KR1020187005843A patent/KR102138447B1/ko active IP Right Grant
- 2016-08-01 EP EP16832289.9A patent/EP3330290A4/en active Pending
- 2016-08-01 JP JP2018524526A patent/JP6946289B2/ja active Active
- 2016-08-01 EP EP16832290.7A patent/EP3348571A4/en active Pending
- 2016-08-01 JP JP2018524525A patent/JP6873992B2/ja active Active
- 2016-08-01 US US15/748,438 patent/US20180291103A1/en not_active Abandoned
- 2016-08-01 WO PCT/CN2016/092679 patent/WO2017020801A1/zh active Application Filing
- 2016-08-01 AU AU2016302951A patent/AU2016302951B2/en active Active
- 2016-08-01 US US15/748,421 patent/US11225522B2/en active Active
- 2016-08-01 CA CA2994339A patent/CA2994339C/en active Active
- 2016-08-01 BR BR112018002130-0A patent/BR112018002130A2/pt active Search and Examination
-
2018
- 2018-01-29 PH PH12018500233A patent/PH12018500233A1/en unknown
- 2018-08-28 HK HK18111076.4A patent/HK1251591A1/zh unknown
- 2018-09-26 HK HK18112311.7A patent/HK1252955A1/zh unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112018002130A2 (pt) | anticorpo de domínio único e proteínas derivadas respectivas contra um ligante de morte programada (pdl1) | |
CO2018000104A2 (es) | Moléculas de anticuerpo que se unen a cd22 | |
EA201890285A1 (ru) | Антитела против pd-1, активируемые антитела против pd-1 и способы их применения | |
BR112018011781A2 (pt) | molécula biespecífica possuindo um ou mais sítios de ligação a epítopo capazes de ligação imunoespecífica a (um) epítopo(s) de pd-1 e um ou mais sítios de ligação a epítopo capazes de ligação imunoespecífica a (um) epítopo(s) de ctla-4, e composição farmacêutica | |
MX2022003891A (es) | Anticuerpos anti-muc16 y sus usos. | |
MX2020001513A (es) | Agentes de union a clec9a y su uso. | |
EA201890278A1 (ru) | Антитела к pd-l1 | |
BR112017010324A2 (pt) | método para tratar ou retardar a progressão de um câncer em um indivíduo, moléculas, métodos para aumentar a função imune em um indivíduo e para selecionar um paciente para tratamento, kits, composição farmacêutica e usos de uma combinação de uma molécula | |
WO2018226578A8 (en) | Nectin-4 binding proteins and methods of use thereof | |
EA201700181A1 (ru) | Композиции аденозиндеаминазы-2 (ада-2), их варианты и способы использования | |
BR112017006825A2 (pt) | anticorpos contra receptor do fator de necrose tumoral induzido por glicocorticoides (gitr) e seus métodos de utilização | |
BR112018000632A8 (pt) | Moléculas de anticorpo que ligam a cd79 | |
EP3603670A4 (en) | MEDICAL COMPOSITION FOR THE PREVENTION AND / OR TREATMENT OF BLOOD CLOG FACTOR IX ANOMALY WITH A MULTI-SPECIFIC ANTIGIBINDING MOLECULAR FUNCTION OF BLOOD CLOTHING FACTOR VIII | |
BR112015000776A2 (pt) | Agentes de ligação à rspo3 e usos dos mesmos | |
BR112018068678A2 (pt) | anticorpos anti-mica | |
BR112017018872A2 (pt) | combinação de um antagonista pd-1 e eribulina para tratamento de câncer | |
BR112018009361A2 (pt) | composições e métodos para o tratamento de doenças autoimunes e de câncer | |
BR112016027043A8 (pt) | combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer | |
BR112015023074A2 (pt) | agentes de ligação-met e uso dos mesmos | |
BR112015019873A2 (pt) | inibidores macrocíclicos da lrrk2 cinase | |
TR201910866T4 (tr) | Kanser tedavisi için birleşik preparasyonlar. | |
HK1244462A1 (zh) | 作為用於癌症治療和診斷之靶標的磷酸甘油酸激酶1的蛋白激酶活性 | |
CO2017001087A2 (es) | Anticuerpos anti proteína similar a angiopoyetina 4 | |
UY36261A (es) | Anticuerpos anti proteína similar a angiopoyetina-4 (angptl4) y métodos de uso | |
BR112019020414A2 (pt) | composições e métodos para detectar e tratar câncer de próstata usando moléculas de ligação à progastrina |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
B25C | Requirement related to requested transfer of rights |
Owner name: SUZHOU ALPHAMAB CO., LTD. (CN) ; 3D MEDICINES (BEIJING) CO., LTD. (CN) |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B25K | Entry of change of name and/or headquarter and transfer of application, patent and certificate of addition of invention: republication |
Owner name: SUZHOU ALPHAMAB CO., LTD. (CN) ; 3D MEDICINES (BEIJING) CO., LTD. (CN) Free format text: REPUBLICACAO DO DESPACHO 25.3 DA RPI 2587 DE 04/08/2020 COM O MESMO TEOR E UM PRAZO 60 DIAS A CONTAR DESTA PUBLICACAO PARA O CUMPRIMENTO DA EXIGENCIA. |
|
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B25B | Requested transfer of rights rejected |
Owner name: SUZHOU ALPHAMAB CO., LTD. (CN) ; 3D MEDICINES (BEIJING) CO., LTD. (CN) Free format text: INDEFERIDO O PEDIDO DE TRANSFERENCIA CONTIDO NA PETICAO 870200077054 DE 19/06/2020, POR AUSENCIA DE CUMPRIMENTO DA EXIGENCIA PUBLICADA NA RPI NO 2596, DE 06/10/2020. |
|
B25C | Requirement related to requested transfer of rights |
Owner name: SUZHOU ALPHAMAB CO., LTD. (CN) ; 3D MEDICINES (BEIJING) CO., LTD. (CN) Free format text: A FIM DE ATENDER A TRANSFERENCIA, REQUERIDA ATRAVES DA PETICAO NO 870210017224 DE 22/02/2021, E NECESSARIO APRESENTAR PROCURACAO EM NOME DA CESSIONARIA, ALEM DA GUIA DE CUMPRIMENTO DE EXIGENCIA. |
|
B25A | Requested transfer of rights approved |
Owner name: 3D MEDICINES (BEIJING) CO., LTD. (CN) ; JIANGSU ALPHAMAB BIOPHARMACEUTICALS CO., LTD (CN) |